193 related articles for article (PubMed ID: 2189623)
21. Does blood pressure reduction necessarily compromise cardiac function or renal hemodynamics? Effects of the angiotensin-converting enzyme inhibitor quinapril.
Kjeldsen SE; Gupta RK; Krause L; Weder AB; Julius S
Am Heart J; 1992 May; 123(5):1433-8. PubMed ID: 1575171
[TBL] [Abstract][Full Text] [Related]
22. Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril.
Edling O; Bao G; Feelisch M; Unger T; Gohlke P
J Pharmacol Exp Ther; 1995 Nov; 275(2):854-63. PubMed ID: 7473177
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride.
Friehe H; Ney P
Arzneimittelforschung; 1997 Feb; 47(2):132-44. PubMed ID: 9079232
[TBL] [Abstract][Full Text] [Related]
24. Hemodynamic effects of quinapril, a novel angiotensin-converting enzyme inhibitor.
Gupta RK; Kjeldsen SE; Krause L; Kneisley J; Posvar E; Weder AB; Julius S
Clin Pharmacol Ther; 1990 Jul; 48(1):41-9. PubMed ID: 2196144
[TBL] [Abstract][Full Text] [Related]
25. Clinical pharmacology of quinapril in healthy volunteers and in patients with hypertension and congestive heart failure.
Sedman AJ; Posvar E
Angiology; 1989 Apr; 40(4 Pt 2):360-9. PubMed ID: 2539762
[TBL] [Abstract][Full Text] [Related]
26. Ventricular remodeling after myocardial infarction and effects of ACE inhibition on hemodynamics and scar formation in SHR.
Zdrojewski T; Gaudron P; Whittaker P; Poelzl S; Schiemann J; Hu K; Ertl G
Cardiovasc Pathol; 2002; 11(2):88-93. PubMed ID: 11934599
[TBL] [Abstract][Full Text] [Related]
27. Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril.
Materson BJ
Am J Cardiol; 1992 Apr; 69(10):46C-53C. PubMed ID: 1546639
[TBL] [Abstract][Full Text] [Related]
28. Protective effect of quinaprilat, an active metabolite of quinapril, on Ca2+-overload induced by lysophosphatidylcholine in isolated rat cardiomyocytes.
Ma H; Hashizume H; Hara A; Yazawa K; Abiko Y
Jpn J Pharmacol; 1999 Jan; 79(1):17-24. PubMed ID: 10082313
[TBL] [Abstract][Full Text] [Related]
29. Acute and long-term dose-response study of quinapril on hormonal profile and tissue angiotensin-converting enzyme in Wistar rats.
Schaison FH; Fernando Ramirez-Gil J; Ciferri S; Bernard M; Baudin B; Mougenot N; Carayon A; Lechat P
J Cardiovasc Pharmacol; 1996 Jul; 28(1):11-8. PubMed ID: 8797130
[TBL] [Abstract][Full Text] [Related]
30. Angiotensin converting enzyme inhibition prevents polyploidization of cardiomyocytes in spontaneously hypertensive rats with left ventricular hypertrophy.
Panizo-Santos A; Sola JJ; Pardo-Mindán FJ; Hernández M; Cenarruzabeitia E; Díez J
J Pathol; 1995 Dec; 177(4):431-7. PubMed ID: 8568599
[TBL] [Abstract][Full Text] [Related]
31. Quinapril inhibits c-Myc expression and normalizes smooth muscle cell proliferation in spontaneously hypertensive rats.
Díez J; Panizo A; Hernández M; Galindo MF; Cenarruzabeitia E; Pardo Mindán FJ
Am J Hypertens; 1997 Oct; 10(10 Pt 1):1147-52. PubMed ID: 9370386
[TBL] [Abstract][Full Text] [Related]
32. The role of tissue renin-angiotensin systems in hypertension and effects of chronic converting-enzyme inhibition.
Keuneke C; Yacullo R; Metzger R; Hellmann T; Peters J; Ganten D
Eur Heart J; 1990 May; 11 Suppl D():11-6. PubMed ID: 2163328
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of angiotensin-converting enzyme (ACE) in plasma and tissue.
Fabris B; Chen BZ; Pupic V; Perich R; Johnston CI
J Cardiovasc Pharmacol; 1990; 15 Suppl 2():S6-13. PubMed ID: 1691409
[TBL] [Abstract][Full Text] [Related]
34. Quinapril prevents hypertension and enhanced vascular reactivity in nitroarginine-treated rats.
Charpie JR; Charpie PM; Goud C; Pitt B; Webb RC
Blood Press; 1997 Mar; 6(2):117-24. PubMed ID: 9105652
[TBL] [Abstract][Full Text] [Related]
35. Effects of chronic administration of sarpogrelate on systolic blood pressure of spontaneously hypertensive rats: comparison with quinapril.
Setoguchi Y; Ohnuki T; Rashid M; Nakamura T; Hattori K; Nagatomo T; Watanabe K; Mitomi A; Nakazawa M
Pharmacology; 2002 Feb; 64(2):71-5. PubMed ID: 11803246
[TBL] [Abstract][Full Text] [Related]
36. ACE inhibitors in the treatment of hypertension in the older patient.
Canter D; Frank G
Eur Heart J; 1990 May; 11 Suppl D():33-43. PubMed ID: 2193809
[TBL] [Abstract][Full Text] [Related]
37. Quinapril treatment restores the vasodilator action of insulin in fructose-hypertensive rats.
Uchida T; Okumura K; Ito T; Kamiya H; Nishimoto Y; Yamada M; Tomida T; Matsui H; Hayakawa T
Clin Exp Pharmacol Physiol; 2002; 29(5-6):381-5. PubMed ID: 12010179
[TBL] [Abstract][Full Text] [Related]
38. Effects of the converting enzyme inhibitor quinapril (CI-906) on blood pressure, renin-angiotensin system, and prostanoids in essential hypertension.
Säynävälammi P; Pörsti I; Pörsti P; Nurmi AK; Seppälä E; Manninen V; Vapaatalo H
J Cardiovasc Pharmacol; 1988 Jul; 12(1):88-93. PubMed ID: 2459540
[TBL] [Abstract][Full Text] [Related]
39. Chronic ACE inhibition by quinapril modulates central vasopressinergic system.
Muders F; Elsner D; Jandeleit K; Bahner U; Kromer EP; Kirst I; Riegger GA; Palkovits M
Cardiovasc Res; 1997 Jun; 34(3):575-81. PubMed ID: 9231041
[TBL] [Abstract][Full Text] [Related]
40. The safety profile of quinapril: is there a difference among ACE inhibitors?
Canter D; Frank GJ; Knapp LE; McLain RW
Clin Cardiol; 1990 Jun; 13(6 Suppl 7):VII39-42. PubMed ID: 2189620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
